Cytokinetics to Announce Third Quarter Results on October 30, 2008

SOUTH SAN FRANCISCO, CA, Oct 23 (MARKET WIRE) --
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is
scheduled to report third quarter results on Thursday, October 30, 2008
at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics'
senior management will host a conference call at 4:30 p.m. Eastern Time
to discuss operational and financial results and the company's outlook
for the future.

The conference call will be simultaneously webcast and can be accessed in
the Investor Relations section of Cytokinetics' website at
www.cytokinetics.com. The live audio of the conference call is also
accessible via telephone to investors, members of the news media and the
general public by dialing either (866) 999-CYTK (2985) (United States and
Canada) or (706) 679-3078 (International) and typing in the passcode
57552468.

An archived replay of the webcast will be available via Cytokinetics'
website until November 14, 2008. The replay will also be available via
telephone by dialing (800) 642-1687 (United States and Canada) or (706)
645-9291 (International) and typing in the passcode 57552468 from October
30, 2008 at 5:30 p.m. Eastern Time until November 14, 2008.

About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on the discovery,
development and commercialization of novel small molecule drugs that may
address areas of significant unmet clinical needs. Cytokinetics'
cardiovascular disease program is focused to cardiac myosin, a motor
protein essential to cardiac muscle contraction. Cytokinetics' lead
compound from this program, CK-1827452, a novel small molecule cardiac
myosin activator, entered Phase II clinical trials for the treatment of
heart failure in 2007. Under a strategic alliance established in 2006,
Cytokinetics and Amgen Inc. are performing joint research focused on
identifying and characterizing activators of cardiac myosin as back-up and
follow-on potential drug candidates to CK-1827452. Amgen has obtained an
option for an exclusive license to develop and commercialize CK-1827452,
subject to Cytokinetics' development and commercial participation rights.
Cytokinetics' cancer program is focused on mitotic kinesins, a family of
motor proteins essential to cell division. Under a strategic alliance
established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting
research and development activities focused on the potential treatment of
cancer. Cytokinetics is developing two novel drug candidates that have
arisen from this program, ispinesib and SB-743921, each a novel inhibitor
of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is
conducting a Phase I clinical trial of ispinesib as monotherapy as a
first-line treatment in chemotherapy-naive patients with locally advanced
or metastatic breast cancer. In addition, Cytokinetics is conducting a
Phase I trial of SB-743921 in patients with non-Hodgkin or Hodgkin
lymphoma. GSK has an option for the joint development and
commercialization of ispinesib and SB-743921. Cytokinetics and GSK are
conducting collaborative research activities directed to the mitotic
kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E
inhibitor, is being developed under the strategic alliance by GSK; GSK
began a Phase I clinical trial with GSK-923295 in 2007. In April 2008,
Cytokinetics announced the selection of a potential drug candidate
directed towards skeletal muscle contractility which may be developed as
a potential treatment for skeletal muscle weakness associated with
neuromuscular diseases or other conditions. All of these drug candidates
and potential drug candidates have arisen from Cytokinetics' research
activities and are directed towards the cytoskeleton. The cytoskeleton is
a complex biological infrastructure that plays a fundamental role within
every human cell. Additional information about Cytokinetics can be
obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include, but are
not limited to, statements relating to the potential benefits of
Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual
results may differ materially due to various risks and uncertainties,
including, but not limited to, potential difficulties or delays in the
development, testing, regulatory approval or production of Cytokinetics'
drug candidates that could slow or prevent clinical development and
product approval, including risks that current and past results of
clinical trials or preclinical studies may not be indicative of future
clinical trials results and Cytokinetics' drug candidates may have
adverse side effects or inadequate therapeutic efficacy. For further
information regarding these and other risks related to Cytokinetics'
business, investors should consult Cytokinetics' filings with the
Securities and Exchange Commission.

Contacts:
Cytokinetics, Incorporated
Christopher S. Keenan (Investors)
Director, Investor Relations
(650) 624-3000

Copyright 2008, Market Wire, All rights reserved.

-0-